These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 17048976

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR.
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP.
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [Abstract] [Full Text] [Related]

  • 11. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK.
    Circulation; 2008 Jun 24; 117(25):3199-205. PubMed ID: 18559696
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP.
    J Clin Pharmacol; 2007 Feb 24; 47(2):192-200. PubMed ID: 17244770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
    Yan JH, Jarugula V, Sabo R, Papst CC, Zhang J, Dole WP.
    J Clin Pharmacol; 2012 May 24; 52(5):645-55. PubMed ID: 21659626
    [Abstract] [Full Text] [Related]

  • 16. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren.
    Tapaninen T, Neuvonen PJ, Niemi M.
    Eur J Clin Pharmacol; 2010 May 24; 66(5):497-502. PubMed ID: 20179914
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL.
    J Renin Angiotensin Aldosterone Syst; 2009 Sep 24; 10(3):157-67. PubMed ID: 19617271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.